Drug Profile
WNT 974
Alternative Names: LGK-974; NVP-LGK974; WNT-974Latest Information Update: 29 Jul 2022
Price :
$50
*
At a glance
- Originator Novartis
- Developer Array BioPharma; Novartis Oncology
- Class Antineoplastics; Pyrazines; Pyridines; Small molecules
- Mechanism of Action PORCN protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer
- Phase I Solid tumours
Most Recent Events
- 29 Jul 2022 WNT 974 is still in phase I trials for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, Combination therapy) in Netherlands, Spain and USA (PO) (Novartis pipeline, June 2022)
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (PO)
- 28 May 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO)